X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Torrent Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs TORRENT PHARMA - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS TORRENT PHARMA IPCA LABS/
TORRENT PHARMA
 
P/E (TTM) x 27.7 25.9 107.0% View Chart
P/BV x 2.1 6.3 33.5% View Chart
Dividend Yield % 0.2 3.2 7.7%  

Financials

 IPCA LABS   TORRENT PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-17
TORRENT PHARMA
Mar-16
IPCA LABS/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs6431,720 37.4%   
Low Rs5031,134 44.4%   
Sales per share (Unadj.) Rs254.4394.5 64.5%  
Earnings per share (Unadj.) Rs16.1101.8 15.8%  
Cash flow per share (Unadj.) Rs29.8116.3 25.6%  
Dividends per share (Unadj.) Rs1.0040.00 2.5%  
Dividend yield (eoy) %0.22.8 6.2%  
Book value per share (Unadj.) Rs194.6200.3 97.1%  
Shares outstanding (eoy) m126.20169.22 74.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.33.6 62.3%   
Avg P/E ratio x35.714.0 254.3%  
P/CF ratio (eoy) x19.212.3 156.9%  
Price / Book Value ratio x2.97.1 41.3%  
Dividend payout %6.239.3 15.8%   
Avg Mkt Cap Rs m72,300241,435 29.9%   
No. of employees `00013.310.9 122.1%   
Total wages/salary Rs m6,9608,559 81.3%   
Avg. sales/employee Rs Th2,413.56,129.6 39.4%   
Avg. wages/employee Rs Th523.2785.8 66.6%   
Avg. net profit/employee Rs Th152.41,581.3 9.6%   
INCOME DATA
Net Sales Rs m32,10666,764 48.1%  
Other income Rs m2262,156 10.5%   
Total revenues Rs m32,33268,920 46.9%   
Gross profit Rs m4,44827,204 16.3%  
Depreciation Rs m1,7302,461 70.3%   
Interest Rs m2411,859 13.0%   
Profit before tax Rs m2,70325,041 10.8%   
Minority Interest Rs m00 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-1,403 0.0%   
Tax Rs m6756,414 10.5%   
Profit after tax Rs m2,02817,224 11.8%  
Gross profit margin %13.940.7 34.0%  
Effective tax rate %25.025.6 97.5%   
Net profit margin %6.325.8 24.5%  
BALANCE SHEET DATA
Current assets Rs m17,34046,622 37.2%   
Current liabilities Rs m9,55932,843 29.1%   
Net working cap to sales %24.220.6 117.4%  
Current ratio x1.81.4 127.8%  
Inventory Days Days10074 135.1%  
Debtors Days Days5779 72.0%  
Net fixed assets Rs m20,77939,029 53.2%   
Share capital Rs m252846 29.8%   
"Free" reserves Rs m24,49931,400 78.0%   
Net worth Rs m24,55333,890 72.4%   
Long term debt Rs m3,51718,637 18.9%   
Total assets Rs m39,59590,136 43.9%  
Interest coverage x12.214.5 84.5%   
Debt to equity ratio x0.10.5 26.1%  
Sales to assets ratio x0.80.7 109.5%   
Return on assets %5.721.2 27.1%  
Return on equity %8.350.8 16.3%  
Return on capital %10.548.5 21.6%  
Exports to sales %48.643.3 112.2%   
Imports to sales %14.26.9 207.4%   
Exports (fob) Rs m15,61728,934 54.0%   
Imports (cif) Rs m4,5714,584 99.7%   
Fx inflow Rs m15,61729,185 53.5%   
Fx outflow Rs m5,8286,021 96.8%   
Net fx Rs m9,79023,165 42.3%   
CASH FLOW
From Operations Rs m2,76427,132 10.2%  
From Investments Rs m-1,432-7,014 20.4%  
From Financial Activity Rs m-1,591-14,352 11.1%  
Net Cashflow Rs m-2595,767 -4.5%  

Share Holding

Indian Promoters % 45.9 71.5 64.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 7.0 162.4%  
FIIs % 25.3 12.6 200.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 8.8 197.7%  
Shareholders   36,892 26,511 139.2%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   PLETHICO PHARMA  BIOCON LTD  FULFORD INDIA  ALKEM LABORATORIES  AJANTA PHARMA  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Aug 18, 2017 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS